Additional Information
Manufacturer | MERCK SHARP AND DOHME CORPORATION |
Mfg number | 00006-4096-02 |
Active ingredient | Hepatitis A vaccine, inactivated, absorbed |
Pharmaceutical form | Suspension for injection |
Strength | 50U/ml |
Mode of administration | IM |
Storage conditions | 2°C to 8°C |
Class of drug | Vaccines |
Legal category | Prescription only medicine |
Description
VAQTA is a hepatitis A vaccine that is supplied in a prefilled syringe containing 50 units per ml. The vaccine is prescribed to adults (people older than 18 years of age) to prevent them from hepatitis A, a liver disease caused by Hepatitis A Virus (HAV). The vaccine works by triggering the production of antibodies and takes 2 to 4 weeks as an onset to immunize a person against the Hepatitis A virus fully.
This vaccine should not be administered to people who are allergic to the active agent or any of the excipients. Also, it cannot be administered to people with active infection and fever. The healthcare provider must be aware prior if the recipient has any blood clotting issues which result in increased bleeding time.
The dosing follows a booster dose injected after the first dose 6 to 19 months apart. It is administered in the deltoid muscle. People with a risk of bleeding should have the injection under the skin. The dose must not be injected into the blood vessel.